In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.
The CETR program builds on work of previous NIAID-supported research and development programs, including the Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) program, and is intended to complement and enhance ongoing translational and product development activities.
Main Areas of Focus
- To advance discovery, preclinical development, production, licensure and/or use of new or improved medical countermeasures (therapeutics, immunotherapeutics, vaccines, vaccine technologies, and medical diagnostics) or related technologies for emerging and re-emerging infectious diseases
Each multi-project Center is organized around specific themes that address development of a targeted medical countermeasure or technology, and related regulatory barriers.
Dr. Erica Ollmann Saphire of the Viral Hemorrhagic Fever Immunotherapeutic Consortium talks about working with Ebola and the antibodies that fight it.